A 416
Alternative Names: A-416Latest Information Update: 05 Mar 2024
At a glance
- Originator Klus Pharma
- Class Antineoplastics; Small molecules
- Mechanism of Action Axl receptor tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 22 Jan 2024 A 416 is available for licensing as of 22 Jan 2024. https://www.kluspharma.com/contact
- 22 Jan 2024 Preclinical trials in Solid tumours in USA (unspecified route) (Klus Pharma pipeline, January 2024)